TMDX vs. ITGR, LIVN, CNMD, SLNO, INMD, MASI, ALPN, SEM, IMVT, and PRGO
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Integer (ITGR), LivaNova (LIVN), CONMED (CNMD), Soleno Therapeutics (SLNO), InMode (INMD), Masimo (MASI), Alpine Immune Sciences (ALPN), Select Medical (SEM), Immunovant (IMVT), and Perrigo (PRGO). These companies are all part of the "medical" sector.
TransMedics Group (NASDAQ:TMDX) and Integer (NYSE:ITGR) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.
TransMedics Group has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Integer has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
Integer received 288 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 63.39% of users gave Integer an outperform vote while only 54.78% of users gave TransMedics Group an outperform vote.
In the previous week, TransMedics Group had 39 more articles in the media than Integer. MarketBeat recorded 49 mentions for TransMedics Group and 10 mentions for Integer. Integer's average media sentiment score of 0.95 beat TransMedics Group's score of 0.55 indicating that Integer is being referred to more favorably in the news media.
Integer has a net margin of 6.01% compared to TransMedics Group's net margin of -3.43%. Integer's return on equity of 11.25% beat TransMedics Group's return on equity.
99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 7.0% of TransMedics Group shares are held by company insiders. Comparatively, 2.0% of Integer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
TransMedics Group currently has a consensus target price of $119.00, suggesting a potential downside of 6.51%. Integer has a consensus target price of $120.50, suggesting a potential upside of 6.57%. Given Integer's higher possible upside, analysts clearly believe Integer is more favorable than TransMedics Group.
Integer has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Summary
Integer beats TransMedics Group on 11 of the 18 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
TransMedics Group Competitors List
Related Companies and Tools